Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (Nasdaq: QTRX) and PreludeDx announced that AidaBREAST is the first multi-omic assay to predict both 10-year locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
The validation included 922 HR+/HER2- patients with a median follow-up of ~10 years, and the test combines spatial proteomics on the Akoya PhenoImager HT platform with Opal chemistry plus targeted RNA sequencing. Findings will be presented at AACR Annual Meeting 2026 on April 21 at Quanterix booth 2028.
Quanterix (Nasdaq: QTRX) debuts its Content Innovation Engine at AACR 2026, integrating Akoya spatial biology with Quanterix SIMOA immunoassay expertise to accelerate translational and clinical spatial biology. New products and modules include the IO60 Spike-In Module, ADC high-plex content, PhenoCode Molecular Barcoding Kit (early access May 2026), and two ADC lung cancer panels available via Accelerator.
Quanterix will host live in-booth presentations April 20–21 and a large customer poster presence at AACR 2026.
Quanterix (NASDAQ: QTRX) announced its 2026 annual meeting of shareholders will be held virtually on June 9, 2026 at 10:00 AM ET. Stockholders of record as of April 14, 2026 may vote. The company set an April 6, 2026 deadline for shareholder proposals and director nominations.
Additional meeting details and proxy materials will be provided in the company's proxy statement.
Quanterix (NASDAQ: QTRX) reported Q4 2025 revenue of $43.9 million (+25% YoY) and full‑year 2025 revenue of $138.9 million (+1% YoY). GAAP gross margin declined to 45.7% in Q4. The company ended Q4 with $121.6 million in cash and expects cash‑flow breakeven in H2 2026 while guiding 2026 revenue to $169–174 million.
Operationally, Quanterix cited $74 million of cost savings from the Akoya transaction, 94% integration completion, a CMS reimbursement rate of $897 for LucentAD Complete, and a January 2026 510(k) submission for its Alzheimer’s blood test.
Lucent Diagnostics (NASDAQ: QTRX) partnered with Life Line Screening to offer Lucent’s non-invasive blood-based biomarker test nationally, with programs already underway in Florida, California, and Texas. Life Line Screening will use its mobile model to provide testing at community venues and share results to help primary care physicians enable earlier intervention.
Life Line Screening operates in the 48 contiguous states and hosts over 15,000 community events annually, supporting scalable access to testing for Alzheimer’s disease risk and MCI.
Quanterix (Nasdaq: QTRX) said its executive leadership will participate in two investor conferences in March 2026: the 46th Annual TD Cowen Healthcare Conference and the Leerink Global Healthcare Conference 2026. Fireside chats and one-on-one meetings are scheduled with webcasts available.
TD Cowen fireside chat: March 4, 2026 at 11:50 am ET. Leerink fireside chat: March 9, 2026 at 1:00 pm ET. According to the company, live and recorded webcasts will be available on the Investors section of the company website.
Quanterix (Nasdaq: QTRX) will report fourth quarter and full year 2025 financial results on March 2, 2026. The company will issue a press release after market close and host a conference call at 4:30 p.m. ET the same day to discuss the results.
Investors can join via dial-in (800-715-9871 or 646-307-1963, conference ID 7904928) or via live webcast on the company website; an archived replay will be available for one year.
Quanterix (Nasdaq: QTRX) submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test to aid detection of Alzheimer’s disease in patients with cognitive symptoms. The test uses Simoa technology and a five-analyte panel (p-Tau217, Aβ42, Aβ40, GFAP, NfL) and is supported by clinical evidence from over 1,800 symptomatic patients across three cohorts and prior Breakthrough Device designation.
The submission aims to offer a non-invasive, quantitative assessment of amyloid, tau, neuroinflammation, and axonal damage to improve diagnostic clarity, especially in early-stage cases.
Quanterix (NASDAQ: QTRX) highlighted a JAMA Network Open study showing a multi‑analyte blood panel—measuring Aβ42/Aβ40, p‑Tau217, GFAP, and NfL with Simoa® technology—better predicts progression from subjective cognitive decline (SCD).
The Amsterdam UMC study followed nearly 300 individuals for up to 15 years and reported an optimal multi‑analyte model C‑index of 0.90, while a single baseline multi‑marker measurement outperformed standalone p‑Tau217. Quanterix notes the same biomarkers are used in its LucentAD Complete multi‑analyte laboratory test.
Quanterix (NASDAQ: QTRX) announced that on January 15, 2026 it granted inducement awards to four new employees under its 2025 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4). The grants comprise 88,050 RSUs and options to purchase an aggregate of 125,745 shares at an exercise price of $7.95 per share (the closing price on the grant date). RSUs and options vest 25% after one year, then monthly over 36 months; options have a 10-year term. Awards were approved by the Compensation Committee.